X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs SUN PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH SUN PHARMA PANACEA BIOTECH/
SUN PHARMA
 
P/E (TTM) x -19.8 36.9 - View Chart
P/BV x 2.8 4.1 67.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   SUN PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
SUN PHARMA
Mar-17
PANACEA BIOTECH/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs149842 17.7%   
Low Rs82572 14.4%   
Sales per share (Unadj.) Rs84.1131.6 63.9%  
Earnings per share (Unadj.) Rs-18.332.7 -56.0%  
Cash flow per share (Unadj.) Rs-6.738.0 -17.6%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs83.7152.7 54.8%  
Shares outstanding (eoy) m61.252,399.26 2.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.45.4 25.5%   
Avg P/E ratio x-6.321.6 -29.2%  
P/CF ratio (eoy) x-17.218.6 -92.6%  
Price / Book Value ratio x1.44.6 29.8%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m7,0741,696,877 0.4%   
No. of employees `0002.817.5 15.7%   
Total wages/salary Rs m1,44949,023 3.0%   
Avg. sales/employee Rs Th1,874.118,028.3 10.4%   
Avg. wages/employee Rs Th527.02,798.8 18.8%   
Avg. net profit/employee Rs Th-407.74,479.5 -9.1%   
INCOME DATA
Net Sales Rs m5,154315,784 1.6%  
Other income Rs m1006,232 1.6%   
Total revenues Rs m5,254322,016 1.6%   
Gross profit Rs m-766100,893 -0.8%  
Depreciation Rs m71112,648 5.6%   
Interest Rs m1,5033,998 37.6%   
Profit before tax Rs m-2,88190,479 -3.2%   
Minority Interest Rs m110-   
Prior Period Items Rs m-699 -5.7%   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m1712,116 0.1%   
Profit after tax Rs m-1,12178,462 -1.4%  
Gross profit margin %-14.931.9 -46.5%  
Effective tax rate %-0.613.4 -4.4%   
Net profit margin %-21.824.8 -87.6%  
BALANCE SHEET DATA
Current assets Rs m3,810329,537 1.2%   
Current liabilities Rs m8,365178,870 4.7%   
Net working cap to sales %-88.447.7 -185.2%  
Current ratio x0.51.8 24.7%  
Inventory Days Days15679 197.1%  
Debtors Days Days6783 80.8%  
Net fixed assets Rs m14,480204,766 7.1%   
Share capital Rs m612,399 2.6%   
"Free" reserves Rs m903363,997 0.2%   
Net worth Rs m5,127366,397 1.4%   
Long term debt Rs m5,83214,361 40.6%   
Total assets Rs m19,433614,102 3.2%  
Interest coverage x-0.923.6 -3.9%   
Debt to equity ratio x1.10 2,901.9%  
Sales to assets ratio x0.30.5 51.6%   
Return on assets %2.013.4 14.6%  
Return on equity %-21.921.4 -102.1%  
Return on capital %3.624.8 14.6%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53944,118 3.5%   
Fx outflow Rs m94224,484 3.8%   
Net fx Rs m59719,634 3.0%   
CASH FLOW
From Operations Rs m59970,822 0.8%  
From Investments Rs m-438-42,216 1.0%  
From Financial Activity Rs m-303-22,854 1.3%  
Net Cashflow Rs m-1416,107 -2.3%  

Share Holding

Indian Promoters % 74.5 63.7 117.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 5.1 11.7%  
FIIs % 1.3 23.0 5.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 8.3 284.3%  
Shareholders   10,259 133,026 7.7%  
Pledged promoter(s) holding % 35.1 0.5 6,617.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DR. REDDYS LAB  IPCA LABS  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  ALEMBIC PHARMA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

SUN PHARMA at 52 Week High; BSE 500 Index Up 1.0% (Market Updates)

Aug 17, 2018 | Updated on Aug 17, 2018

SUN PHARMA share price has hit a 52-week high. It is presently trading at Rs 624. BSE 500 Index is up by 0.5% at 15,438. Within the BSE 500, SUN PHARMA (up 0.7%) and MINDTREE LTD (up 9.7%) are among the top gainers, while top losers are TECHNO ELECTRIC and RELIANCE NAVAL & ENGINEERING LTD.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 17, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS